Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 2
1965 1
1966 1
1967 2
1969 4
1970 6
1971 3
1972 5
1973 7
1974 4
1975 2
1976 4
1977 6
1978 8
1979 4
1980 5
1981 5
1982 9
1983 9
1984 9
1985 11
1986 12
1987 14
1988 10
1989 20
1990 18
1991 21
1992 14
1993 23
1994 32
1995 33
1996 39
1997 64
1998 76
1999 87
2000 105
2001 146
2002 148
2003 197
2004 232
2005 313
2006 352
2007 435
2008 512
2009 598
2010 636
2011 744
2012 764
2013 833
2014 868
2015 949
2016 987
2017 950
2018 984
2019 1063
2020 1112
2021 1113
2022 751
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

13,666 results
Results by year
Filters applied: . Clear all
Page 1
Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.
Kim BK, Hong SJ, Lee YJ, Hong SJ, Yun KH, Hong BK, Heo JH, Rha SW, Cho YH, Lee SJ, Ahn CM, Kim JS, Ko YG, Choi D, Jang Y, Hong MK; RACING investigators. Kim BK, et al. Among authors: kim js. Lancet. 2022 Jul 30;400(10349):380-390. doi: 10.1016/S0140-6736(22)00916-3. Epub 2022 Jul 18. Lancet. 2022. PMID: 35863366 Clinical Trial.
Vascular vertigo and dizziness: Diagnostic criteria.
Kim JS, Newman-Toker DE, Kerber KA, Jahn K, Bertholon P, Waterston J, Lee H, Bisdorff A, Strupp M. Kim JS, et al. J Vestib Res. 2022;32(3):205-222. doi: 10.3233/VES-210169. J Vestib Res. 2022. PMID: 35367974 Free PMC article.
Forum on Biospecies Sensors.
James T, Yoon J, Wang S, Kim JS. James T, et al. Among authors: kim js. ACS Appl Bio Mater. 2021 Mar 15;4(3):2231-2232. doi: 10.1021/acsabm.1c00164. ACS Appl Bio Mater. 2021. PMID: 35014347 No abstract available.
Induction and Maintenance Treatment of Lupus Nephritis: A Comprehensive Review of Meta-Analyses.
Shin JI, Li H, Park S, Yang JW, Lee KH, Jo Y, Park S, Oh J, Kim H, An HJ, Jeong G, Jung H, Lee HJ, Kim JS, Nam SW, Koyanagi A, Jacob L, Hwang J, Yon DK, Lee SW, Tizaoui K, Kronbichler A, Kim JH, Smith L. Shin JI, et al. Among authors: kim js. J Clin Med. 2022 Jan 11;11(2):343. doi: 10.3390/jcm11020343. J Clin Med. 2022. PMID: 35054037 Free PMC article. Review.
Retraction: The Reversible Fourth-Generation EGFR Tyrosine Kinase Inhibitor OBX02-011 Overcomes C797S-Mediated Resistance in Lung Cancer.
Choi YJ, Kim DS, Sung YH, Kim DH, Im K, Lee H, Lee CW, Cho J, Min J, Woo DC, Kim SE, Lee S, Kong YJ, Ryu HC, Kim JS, Rengasamy R, Ji W, Choi CM, Lee JC, Rho JK. Choi YJ, et al. Among authors: kim js. Cancer Res. 2022 Aug 26:OF1. doi: 10.1158/0008-5472.CAN-22-2507. Online ahead of print. Cancer Res. 2022. PMID: 36018295 No abstract available.
Nanoliposomal Ratiometric Fluorescent Probe toward ONOO- Flux.
Zhang J, Kan J, Sun Y, Won M, Kim JH, Zhang W, Zhou J, Qian Z, Kim JS. Zhang J, et al. Among authors: kim js. ACS Appl Bio Mater. 2021 Mar 15;4(3):2080-2088. doi: 10.1021/acsabm.0c01178. Epub 2020 Nov 6. ACS Appl Bio Mater. 2021. PMID: 35014335
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
Cho BC, Han JY, Kim SW, Lee KH, Cho EK, Lee YG, Kim DW, Kim JH, Lee GW, Lee JS, Shim BY, Kim JS, Chun SH, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Lee Y, Lee DH, Kang JA, Lee N, Kwon MJ, Espenschied C, Yablonovitch A, Ahn MJ. Cho BC, et al. Among authors: kim js. J Thorac Oncol. 2022 Apr;17(4):558-567. doi: 10.1016/j.jtho.2021.11.025. Epub 2021 Dec 24. J Thorac Oncol. 2022. PMID: 34958928 Free article. Clinical Trial.
13,666 results
You have reached the last available page of results. Please see the User Guide for more information.